Showing recent highlights
What's New
The Lancet · September 3, 2026
Researchers found that people with Down syndrome who develop seizures later in life may be experiencing an early warning sign of Alzheimer's disease progression — meaning the seizures aren't just a separate problem, but may actually be connected to the brain changes caused by Alzheimer's and could even speed up those changes. This matters because these seizures are often missed or left untreated in the early stages, and better understanding the link could help doctors recognize Alzheimer's-related decline sooner in people with Down syndrome. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that being physically active — whether through hobbies and exercise, household chores, or commuting on foot or by bike — may be linked to a lower risk of developing Alzheimer's disease and other forms of dementia, though the benefit varied depending on the type of activity. Interestingly, not all physical activity appeared equal: the context in which people moved their bodies seemed to matter, meaning that leisurely exercise and daily life movement may each play their own role in protecting the brain. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a drug called blarcamesine, taken as a pill, may help protect brain cells in people with early or mild-to-moderate Alzheimer's disease — a condition that causes memory loss and thinking problems that worsen over time. Unlike some existing Alzheimer's treatments that require an IV infusion, this one can be swallowed, which could make it easier for patients to use. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that cannabinoid-based therapies — meaning treatments derived from cannabis — may help reduce agitation and other difficult behaviors in people with Alzheimer's disease. Looking at seven studies involving 221 participants, researchers saw some promising signs that these treatments could ease restlessness and aggression, which are symptoms that can be very hard on both patients and the family members caring for them. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · September 1, 2026
Researchers found that a medication called brexpiprazole (brand name Rexulti) helped reduce agitation, aggression, irritability, and anxiety in people with Alzheimer's disease over a 12-week period. The study also found that caregivers — the family members or helpers supporting those patients — reported feeling less distressed and overwhelmed compared to caregivers of patients who received a placebo (a pill with no active medicine). This appears to be a new research finding about how this medication may help manage some of the more difficult behavioral symptoms of Alzheimer's disease, which can be hard on both patients and the people who care for them.
Ask your doctor: Ask the doctor whether brexpiprazole might help reduce agitation in the patient and make things easier for their caregivers.
What's New
PubMed · September 1, 2026
Researchers found that certain types of exercise — specifically resistance training, Pilates, and high-intensity interval training (HIIT) — were linked to lower levels of a protein in the blood called neurofilament light chain, which is a marker of nerve damage, in people with multiple sclerosis (MS). This is meaningful because lower levels of this marker may suggest that nerve cells are being damaged less, though it's important to know that not all exercise types showed this effect — longer, moderate aerobic exercise did not produce the same result. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that newer Alzheimer's treatments called anti-amyloid antibodies — medications designed to clear a harmful protein buildup in the brain — carry a meaningful risk of side effects seen on brain scans, including swelling and small bleeds in the brain. Across 22 studies involving more than 23,000 people, about 1 in 15 experienced brain swelling and about 1 in 6 showed signs of tiny brain bleeds, with some medications showing higher risks than others; people who carry a gene variant called APOE ε4 — which is linked to a higher Alzheimer's risk — appeared to face an even greater chance of these side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a specific combination of nutrients — designed to help the brain build and maintain the connections between brain cells — may have a small benefit for people in the early stages of Alzheimer's disease, particularly those with mild memory problems who weren't yet on other medications, but the effect was too small to be considered statistically reliable across the full range of patients studied. Interestingly, the results suggest that the stage of the disease may matter — meaning the same supplement might work differently depending on how far along someone's Alzheimer's has progressed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 27, 2026
Researchers found that a simple blood test measuring a protein called p-tau217 — which builds up in the brain during Alzheimer's disease — can accurately detect Alzheimer's-related brain changes without needing an expensive brain scan. Across 25 studies involving over 18,000 people, the blood test correctly identified Alzheimer's brain changes in roughly 9 out of 10 cases, and combining p-tau217 with another protein marker made the test even more reliable. This matters because a widely available, affordable blood test could make it much easier to diagnose Alzheimer's earlier and more accurately. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 25, 2026
Researchers found that in studies testing new Alzheimer's treatments, most trials measured things like memory and thinking skills, overall health status, and ability to handle daily tasks — but very few paid attention to the quality of life of patients or their caregivers. This matters because for someone living with Alzheimer's disease, how well they can enjoy daily life and how much strain falls on the people caring for them are hugely important, yet these pieces are often left out of the research picture. This is early research and hasn't yet changed treatment guidelines.
Medications
JAMA · August 25, 2026
Researchers found that the FDA approved a new way for people with Alzheimer's disease to begin taking lecanemab (brand name Leqembi), a medication that targets and helps clear a harmful protein buildup in the brain called amyloid, which is linked to Alzheimer's. The new approval means patients can start their first doses at home using an injection under the skin, rather than having to go to a clinic — which could make starting this treatment much more convenient. This represents a new option in how the treatment is delivered, expanding on a medication that was already available.
Ask your doctor: Ask the doctor whether the patient could start lecanemab-irmb injections at home instead of having to go to a clinic for the first dose.
What's New
PubMed · August 25, 2026
Researchers found that certain nutrients — including omega-3 fatty acids (healthy fats found in fish), B vitamins, vitamin D, and dietary approaches that influence gut bacteria — may help reduce brain inflammation, which is thought to play a major role in Alzheimer's disease and early memory problems. The review looked at 22 studies and found that these nutritional approaches showed promising effects on the biological markers linked to that inflammation. This could matter for people with Alzheimer's disease because it suggests that what someone eats might influence some of the harmful processes happening in the brain — though exactly how much that translates into real-world benefits for memory or thinking is still being worked out. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · August 17, 2026
Scientists discovered that blocking a specific protein in the brain may help prevent the buildup of amyloid — a sticky substance that clumps together and damages brain cells in people with Alzheimer's disease. In mice, an experimental treatment stopped these harmful clumps from forming, helped brain cells live longer, and even showed some benefits for heart health. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · August 14, 2026
A large study of more than 21,000 women found that those who used estrogen-only hormone therapy later in life were significantly less likely to be diagnosed with dementia or show the brain changes linked to Alzheimer's disease — such as the protein buildup (called amyloid plaques and tau tangles) that doctors look for in brain tissue. Women who used this therapy had about 39% lower odds of a dementia diagnosis and 35% lower odds of those tell-tale brain changes. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · August 4, 2026
Researchers found that new blood tests can now detect early signs of Alzheimer's disease, and this raises important questions about how doctors and patients talk about end-of-life wishes — including the option of physician-assisted dying, where a doctor legally helps a patient end their life in places where that is allowed. For someone with Alzheimer's, knowing about the disease earlier might give them more time to have these deeply personal conversations with their doctor and loved ones while they can still clearly express what they want. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a treatment called rTMS — which uses magnetic pulses directed at the brain to stimulate nerve activity — was being studied as a possible option for people with Alzheimer's disease, and this study looked closely at the side effects that occurred during that trial. They found that the most common side effects were general pain or discomfort and muscle twitching, and that higher levels of stimulation tended to be linked to more of these physical side effects. This matters because understanding who is more likely to experience side effects, and why, could help make the treatment safer and more comfortable for people with Alzheimer's if it moves forward. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with early Alzheimer's disease or mild memory problems who did six months of structured brain-training exercises on a computer showed meaningful improvements in memory, daily functioning, and anxiety — and also had lower levels of inflammation in their blood (inflammation is the body's overactive response that can contribute to brain damage over time). What made this especially interesting is that brain scans still showed the disease progressing, yet people's thinking and daily skills improved anyway, suggesting the brain may find new ways to cope even as it changes. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · August 1, 2026
Researchers found that brexpiprazole (brand name Rexulti), a medication approved to treat agitation in people with Alzheimer's disease, had a safety profile similar to a placebo — meaning people taking it experienced side effects at roughly the same rate and timing as those taking a sugar pill. This is considered a newer, officially approved option, since agitation in Alzheimer's was previously managed with medications used 'off-label,' meaning they weren't specifically approved for that purpose. The study tracked side effects over 12 to 24 weeks across more than 1,000 participants to get a clearer picture of when side effects tended to appear and how long they lasted.
What's New
PubMed · August 1, 2026
Researchers found that treatments using mesenchymal stem cells — a type of cell harvested from the body that may help protect the brain and calm inflammation — showed mixed results for people with Alzheimer's disease. Overall, the treatments did not clearly improve thinking or memory scores compared to a placebo (a dummy treatment with no active ingredient), but when researchers looked specifically at lower doses, there were some promising signs of benefit in thinking and memory. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers analyzed data from 75 studies involving more than 68,000 people with Alzheimer's disease to compare how well different types of treatments work. They found that medications targeting brain chemical messengers — such as drugs that help preserve a chemical called acetylcholine, which supports memory and thinking — consistently showed the strongest benefits for slowing cognitive decline, meaning the gradual loss of memory and thinking skills. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with Alzheimer's disease tend to have lower levels of certain substances produced by gut bacteria — called short-chain fatty acids — and that these lower levels were linked to greater memory and thinking problems. This is interesting because it suggests that what's happening in the gut may be connected to brain health, and these substances could potentially serve as a way to detect or track Alzheimer's disease through a simple test rather than invasive procedures. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with Alzheimer's disease who used virtual reality (VR) training — interactive, computer-generated environments experienced through a headset or screen — showed meaningful improvements in overall thinking ability and short-term memory compared to those who didn't use it. However, the benefits didn't extend to other areas like planning skills, balance, or the ability to carry out everyday tasks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that sleep problems don't just appear when Alzheimer's disease is fully developed — certain sleep changes, like spending less time in deep, restful sleep stages, can show up much earlier, even in people with only mild memory and thinking difficulties. The study also found that the more advanced the disease, the more disrupted sleep becomes, suggesting that tracking sleep quality over time might help signal how the disease is progressing. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a drug called hydromethylthionine (HMT), which is being studied as a possible treatment for Alzheimer's disease, behaves unexpectedly in the body over time — building up to much higher levels in the blood than scientists originally predicted. This unexpected buildup helped explain why a large clinical trial gave confusing results: the 'inactive' low dose given to the comparison group turned out to be more active than intended, making it harder to tell the two groups apart. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that semaglutide — a diabetes medication like Ozempic or Victoza — showed some signs of slowing decline in people with Alzheimer's disease when data from later time points in two large studies were re-examined, even though the trials were originally declared unsuccessful. The results were modest, and researchers noted that because this medication doesn't easily cross into the brain, newer versions of similar medications designed to reach the brain more effectively might work better. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that women who used a patch-form of estrogen hormone therapy — especially when started early around menopause — showed lower levels of certain brain proteins linked to Alzheimer's disease, as well as less buildup of harmful plaques in the brain. Interestingly, some of these protective effects appeared to last even years after stopping the therapy, though pill-form estrogen or combinations with another hormone called progestin did not show the same benefits. This matters for people with Alzheimer's disease in their family because it suggests the type, timing, and form of hormone therapy may play a role in brain health — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that combining two types of supportive care — 'narrative nursing,' where patients share personal stories with caregivers, and structured mental exercises to reshape negative thinking — helped people with Alzheimer's disease think more clearly, feel less anxious, and manage daily tasks better compared to those who received standard care alone. The improvements showed up after six months and covered not just memory and thinking, but also overall quality of life. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a protein measured in the blood, called p-tau217, was not reliable enough on its own to tell doctors whether a new Alzheimer's drug called donanemab had successfully cleared the sticky protein buildup (called amyloid) from the brain. Even though the blood protein levels did drop during treatment, a brain scan called a PET scan is still needed to get an accurate picture of what's happening. This matters because a simple blood test would be much easier and less costly than a brain scan, so scientists are still searching for better ways to track treatment progress. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a new experimental drug called ABBV-916, given through an IV, was able to reduce the buildup of amyloid — a sticky protein that clumps in the brains of people with Alzheimer's disease and is thought to contribute to memory loss — in people with early Alzheimer's. The drug's ability to clear amyloid and its safety profile were similar to other already-approved Alzheimer's treatments that work the same way, which suggests it could eventually be a contender in this treatment space. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 29, 2026
Researchers found that people living with Alzheimer's disease and several other brain conditions may be at a higher risk of suicidal thoughts or attempts, with depression and feeling socially isolated being the most common warning signs. Interestingly, the pattern in Alzheimer's was less clear than in other conditions studied, making it harder to pinpoint when people might be most vulnerable. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.